All Outputs (8)

Encapsulation of copper phenanthroline within horse spleen apoferritin: characterisation, cytotoxic activity and ability to retain temozolomide (2024)
Journal Article
Cassioli, M. L., Fay, M., Turyanska, L., Bradshaw, T. D., Thomas, N. R., & Pordea, A. (2024). Encapsulation of copper phenanthroline within horse spleen apoferritin: characterisation, cytotoxic activity and ability to retain temozolomide. RSC Advances, 14(20), 14008-14016. https://doi.org/10.1039/d3ra07430g

Protein capsules are promising drug delivery vehicles for cancer research therapies. Apoferritin (AFt) is a self-assembling 12 nm diameter hollow nanocage with many desirable features for drug delivery, however, control of drug retention inside the p... Read More about Encapsulation of copper phenanthroline within horse spleen apoferritin: characterisation, cytotoxic activity and ability to retain temozolomide.

Correction to “Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy” (2023)
Journal Article
Abuzaid, H., Abdelrazig, S., Ferreira, L., Collins, H. M., Kim, D.-H., Lim, K.-H., Kam, T.-S., Thomas, N. R., Turyanska, L., & Bradshaw, T. D. (2024). Correction to “Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy”. ACS Omega, 9(1), Article 2012. https://doi.org/10.1021/acsomega.3c09291

Neil R. Thomas was added as an author. The change in authorship is reflected in the authorship of this Correction.

Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy (2022)
Journal Article
Abuzaid, H., Abdelrazig, S., Ferreira, L., Collins, H. M., Kim, D.-H., Lim, K.-H., …Bradshaw, T. (2022). Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy. ACS Omega, 7(25), 21473-21482. https://doi.org/10.1021/acsomega.2c00997

he O-acetyl (or acetate) derivative of the Aspidosperma alkaloid Jerantinine A (JAa) elicits anti-tumor activity against cancer cell lines including mammary carcinoma cell lines irrespective of receptor status (0.14 < GI50 < 0.38 μM), targeting micro... Read More about Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy.

Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy (2022)
Journal Article
Abuzaid, H., Abdelrazig, S., Ferreira, L., Collins, H. M., Kim, D. H., Lim, K. H., Kam, T. S., Turyanska, L., & Bradshaw, T. D. (2022). Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy. ACS Omega, 7(25), 21473–21482. https://doi.org/10.1021/acsomega.2c00997

The O-acetyl (or acetate) derivative of the Aspidosperma alkaloid Jerantinine A (JAa) elicits anti-tumor activity against cancer cell lines including mammary carcinoma cell lines irrespective of receptor status (0.14 < GI 50 < 0.38 μM), targeting mic... Read More about Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy.

Apoferritin and Dps as drug delivery vehicles: Some selected examples in oncology (2021)
Journal Article
Kuruppu, A. I., Turyanska, L., Bradshaw, T. D., Manickam, S., Galhena, B. P., Paranagama, P., & De Silva, R. (2022). Apoferritin and Dps as drug delivery vehicles: Some selected examples in oncology. BBA - General Subjects, 1866(2), Article 130067. https://doi.org/10.1016/j.bbagen.2021.130067

Background: The ideal nanoparticle should be able to encapsulate either pharmaceutical agents or imaging probes so that it could treat or image clinical tumours by targeting the cancer site efficiently. Further, it would be an added advantage if it d... Read More about Apoferritin and Dps as drug delivery vehicles: Some selected examples in oncology.

Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications (2021)
Journal Article
Al-Ani, A. W., Zamberlan, F., Ferreira, L., Bradshaw, T. D., Thomas, N. R., & Turyanska, L. (2021). Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications. Nano Express, 2(4), Article 040005. https://doi.org/10.1088/2632-959x/ac33b8

We report a new theranostic device based on lead sulfide quantum dots (PbS QDs) with optical emission in the near infrared wavelength range decorated with affibodies (small 6.5 kDa protein-based antibody replacements) specific to the cancer biomarker... Read More about Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications.

New Treatments in Renal Cancer: The AhR Ligands (2020)
Journal Article
Turyanska, L., Itkin, B., Breen, A., Loaiza-Perez, A. I., Sandes, E. O., & Bradshaw, T. D. (2020). New Treatments in Renal Cancer: The AhR Ligands. International Journal of Molecular Sciences, 21(10), Article 3551. https://doi.org/10.3390/ijms21103551

Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl hydrocarbon receptor (AhR) has recently been postulated as a molec... Read More about New Treatments in Renal Cancer: The AhR Ligands.

Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery (2019)
Journal Article
Breen, A. F., Scurr, D., Cassioli, M. L., Wells, G., Thomas, N. R., Zhang, J., …Bradshaw, T. D. (2019). Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery. International Journal of Nanomedicine, 14, 9525-9534. https://doi.org/10.2147/IJN.S226293

Introduction: Advancment of novel anticancer drugs into clinic is frequently halted by their lack of solubility, reduced stability under physiological conditions, and non-specific uptake by normal tissues, causing systemic toxicity. Their progress to... Read More about Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.